GSA Capital Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
Other funds holding AMLX
SVCM
GSA Capital Partners's AMLX Position: Q3 2026 in Review
GSA Capital Partners reduced its Amylyx Pharmaceuticals (AMLX) stake by 75% in Q3 2026, selling an estimated $779K and leaving 9,839 shares worth $286K. The position accounts for 0.02% of the portfolio, ranked #1418.
GSA Capital Partners first reported a position in AMLX in Q1 2023 and has held it in 12 quarters since. The position peaked at $1.95M in Q4 2023. 230 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.
- GSA Capital Partners held 9,839 shares of Amylyx Pharmaceuticals worth $286K as of Q3 2026.
- GSA Capital Partners sold 29,402 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $779K.
- Amylyx Pharmaceuticals made up 0.02% of GSA Capital Partners's portfolio in Q3 2026, its #1418 holding.
- GSA Capital Partners first reported a position in Amylyx Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
- GSA Capital Partners's Amylyx Pharmaceuticals position peaked at $1.95M in Q4 2023.
- 230 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.